Nanomedicine for the prevention, treatment and imaging of atherosclerosis.

Nanomedicine for the prevention, treatment and imaging of atherosclerosis.

Εμφάνιση άλλων εκδόσεων (2)

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in developed countries, with an increasing prevalence due to an aging population. The pathology underpinning CVD is atherosclerosis, a chronic inflammatory state involving the arterial wall. Accumulation of low density lipo...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Psarros, C, Lee, R, Margaritis, M, Antoniades, C
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	2012

Παρόμοια τεκμήρια

Nanomedicine for the prevention, treatment and imaging of atherosclerosis
ανά: Psarros, C, κ.ά.
Έκδοση: (2012)

Nanomedicine for the prevention, treatment and imaging of atherosclerosis.
ανά: Psarros, C, κ.ά.
Έκδοση: (2012)

Nanomedicine for Diagnosis and Treatment of Atherosclerosis
ανά: Jingyun Cheng, κ.ά.
Έκδοση: (2023-12-01)

Construction of dual nanomedicines for the imaging and alleviation of atherosclerosis
ανά: Shuihua Zhang, κ.ά.
Έκδοση: (2020-01-01)

Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis
ανά: Yongfang Lin, κ.ά.
Έκδοση: (2024-06-01)

The role of adiponectin at different stages of atherosclerosis in heart failure: associations with myocardial redox state
ανά: Antonopoulos, A, κ.ά.
Έκδοση: (2010)

Nanoparticles: a promising therapeutic approach in atherosclerosis.
ανά: Antoniades, C, κ.ά.
Έκδοση: (2010)

Biomimetic nanomedicines for precise atherosclerosis theranostics
ανά: Ying Tao, κ.ά.
Έκδοση: (2023-11-01)

Editorial: Advances on targeted nanomedicines for atherosclerosis
ανά: Qinggong Han, κ.ά.
Έκδοση: (2022-10-01)

Macrophage-targeted nanomedicine for the diagnosis and management of atherosclerosis
ανά: Ping Ping Hu, κ.ά.
Έκδοση: (2022-09-01)

Novel therapeutic strategies targeting vascular redox in human atherosclerosis.
ανά: Antonopoulos, A, κ.ά.
Έκδοση: (2009)

Advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implications
ανά: Xue Li, κ.ά.
Έκδοση: (2022-10-01)

Statin treatment improves vascular redox state through a tetrahydrobiopterin-mediated re-coupling of endothelial nitric oxide synthase, in human atherosclerosis
ανά: Antoniades, C, κ.ά.
Έκδοση: (2011)

Precision nanomedicine in atherosclerosis therapy: how far are we from reality?
ανά: Yee Shan Wong, κ.ά.
Έκδοση: (2019-01-01)

Multifunctional phototheranostic nanomedicine for cancer imaging and treatment
ανά: D. Gao, κ.ά.
Έκδοση: (2020-01-01)

Interrelationships between vascular superoxide and adiponectin biosynthesis in perivascular adipose tissue in human atherosclerosis
ανά: Bakogiannis, C, κ.ά.
Έκδοση: (2010)

Shedding new light on atherosclerosis therapeutics: Nanomedicines targeting atherosclerotic immune microenvironment
ανά: Zhiyue Wang, κ.ά.
Έκδοση: (2024-12-01)

Nanomedicine for renal cell carcinoma: imaging, treatment and beyond
ανά: Ruolin Wu, κ.ά.
Έκδοση: (2023-01-01)

Adiponectin as a regulator of vascular redox state in human atherosclerosis
ανά: Margaritis, M
Έκδοση: (2016)

Macrophage-targeting Antisenescence nanomedicine enables in-Situ NO induction for Gaseous and antioxidative atherosclerosis intervention
ανά: Yuanyuan Peng, κ.ά.
Έκδοση: (2025-06-01)

L-Arginine, the substrate for NO synthesis: an alternative treatment for premature atherosclerosis?
ανά: Siasos, G, κ.ά.
Έκδοση: (2007)

A novel cross-talk between perivascular adipose tissue and the arterial wall controls redox state in human atherosclerosis
ανά: Margaritis, M, κ.ά.
Έκδοση: (2013)

A NOVEL CROSS-TALK BETWEEN PERIVASCULAR ADIPOSE TISSUE AND THE ARTERIAL WALL CONTROLS REDOX STATE IN HUMAN ATHEROSCLEROSIS
ανά: Margaritis, M, κ.ά.
Έκδοση: (2013)

Macrophage membrane-functionalized manganese dioxide nanomedicine for synergistic treatment of atherosclerosis by mitigating inflammatory storms and promoting cholesterol efflux
ανά: Sijin Chen, κ.ά.
Έκδοση: (2024-10-01)

Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition
ανά: Akoumianakis, I, κ.ά.
Έκδοση: (2020)

Insulin Treatment Induces Oxidative Stress in the Vascular Wall of Patients With Atherosclerosis Independently of Diabetes or Systemic Insulin Resistance: The Protective Role of DPP-IV Inhibition
ανά: Akoumianakis, I, κ.ά.
Έκδοση: (2018)

An immunoregulator nanomedicine approach for the treatment of tuberculosis
ανά: Luona Yang, κ.ά.
Έκδοση: (2023-05-01)

Challenges to Safe Nanomedicine Treatment
ανά: Chunhua Yang, κ.ά.
Έκδοση: (2023-03-01)

Biomarkers of premature atherosclerosis.
ανά: Kampoli, A, κ.ά.
Έκδοση: (2009)

Nanomedicine: Engineering of a tri-imageable nanoparticle for diagnostics
ανά: Bumb, A, κ.ά.
Έκδοση: (2009)

Prevention and Regression of Atherosclerosis: Emerging Treatments
ανά: Aliosvi Rodríguez Rodríguez, κ.ά.
Έκδοση: (2014-06-01)

Statins in coronary artery bypass grafting surgery: lipid lowering and beyond.
ανά: Margaritis, M, κ.ά.
Έκδοση: (2012)

The role of perivascular fat in the diagnosis and prognosis of atherosclerosis
ανά: Polkinghorne, M, κ.ά.
Έκδοση: (2022)

Homocysteine lowering: any use in atherosclerosis?
ανά: Antoniades, C, κ.ά.
Έκδοση: (2007)

Atorvastatin rapidly reduces myocardial superoxide and peroxynitrite generation in human atherosclerosis, by suppressing NADPH-oxidase activity independently of LDL lowering
ανά: Antoniades, C, κ.ά.
Έκδοση: (2011)

Nanomedicine Explored at Molecular Imaging Summit
ανά: Julie L. Sutcliffe PhD
Έκδοση: (2011-01-01)

The Role of Optical Imaging in Translational Nanomedicine
ανά: Evelien Hesemans, κ.ά.
Έκδοση: (2022-08-01)

Advances in nanomedicines for lymphatic imaging and therapy
ανά: Pan He, κ.ά.
Έκδοση: (2023-08-01)

Nanomedicine for Imaging and Therapy of Pancreatic Adenocarcinoma
ανά: Giulia Brachi, κ.ά.
Έκδοση: (2019-11-01)

Perivascular adipose tissue and coronary atherosclerosis
ανά: Mancio, J, κ.ά.
Έκδοση: (2018)